UB Paderborn / Katalog / Suche / in CDI

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

Journal of clinical oncology, 2008-12, Vol.26 (34), p.5544-5552

2008

Link zum Volltext

Verfügbarkeit prüfen

Metastatic breast cancer in patient with clinical neurofibromatosis type 1

Current problems in cancer. Case reports, 2023-06, Vol.10, p.100240, Article 100240

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study

International journal of gynecological cancer, 2017-01, Vol.27 (1), p.50-58

2017

Link zum Volltext

Verfügbarkeit prüfen

Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study

Journal of thoracic oncology, 2021-09, Vol.16 (9), p.1570-1581

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with cisplatin and gemcitabine (CG) in patients with non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9020-9020

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety, efficacy and biomarker data in patients with non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab in combination with platinum doublet

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9089-9089

2023

Link zum Volltext

Verfügbarkeit prüfen

Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study

Journal of clinical oncology, 2021-11, Vol.39 (32), p.3633-3644

2021

Link zum Volltext

Verfügbarkeit prüfen

Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC

Journal of thoracic oncology, 2024-05

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4141-4141

2022

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer

International journal of gynecological cancer, 2017-02, Vol.27 (2), p.258-266

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS9137-TPS9137

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1013-1013

2019

Link zum Volltext

Verfügbarkeit prüfen

Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study

Journal of thoracic oncology, 2021-09, Vol.16 (9), p.1570-1581

2021

Link zum Volltext

Verfügbarkeit prüfen

Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiracil

Molecular and clinical oncology, 2018-05, Vol.8 (5), p.699-702

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Onartuzumab in Combination with First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non–Small-Cell Lung Cancer

Clinical lung cancer, 2017-01, Vol.18 (1), p.50-59

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2172: Tumor IL1RAP levels and reduction in serum biomarkers correlate with response in PDAC patients treated with nadunolimab, an anti-IL1RAP monoclonal antibody, in combination with gemcitabine and nab-paclitaxel

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2172-2172

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety Results from a Phase II, Placebo-Controlled Study of Onartuzumab plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous Cell Non–Small-Cell Lung Cancer

Clinical lung cancer, 2017-01, Vol.18 (1), p.43-49

2017

Link zum Volltext

Verfügbarkeit prüfen

Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer

Clinical pharmacology in drug development, 2021-10, Vol.10 (10), p.1142-1155

2021

Link zum Volltext

Verfügbarkeit prüfen

IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15079-e15079

2015

Link zum Volltext

Verfügbarkeit prüfen

Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiradl

Molecular and clinical oncology, 2018-05, Vol.8 (5), p.699

2018

Link zum Volltext

Verfügbarkeit prüfen

Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8034-8034

2013

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

Metastatic breast cancer in patient with clinical neurofibromatosis type 1

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study

Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study

Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with cisplatin and gemcitabine (CG) in patients with non-small cell lung cancer (NSCLC)

Safety, efficacy and biomarker data in patients with non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab in combination with platinum doublet

Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study

Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC

Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC)

A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer

Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT)

Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC)

Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study

Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiracil

Efficacy and Safety of Onartuzumab in Combination with First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non–Small-Cell Lung Cancer

Abstract 2172: Tumor IL1RAP levels and reduction in serum biomarkers correlate with response in PDAC patients treated with nadunolimab, an anti-IL1RAP monoclonal antibody, in combination with gemcitabine and nab-paclitaxel

Efficacy and Safety Results from a Phase II, Placebo-Controlled Study of Onartuzumab plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous Cell Non–Small-Cell Lung Cancer

Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer

IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial

Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiradl

FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma

FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma

Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy

Suchergebnisse filtern